Association of Clusterin Levels in Cerebrospinal Fluid with Synaptic Degeneration Across the Alzheimer’s Disease Continuum
Authors Wang J, Zhang X, Zhu B, Fu P
Received 26 July 2019
Accepted for publication 20 December 2019
Published 20 January 2020 Volume 2020:16 Pages 183—190
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Jun Chen
Jun Wang,* Xin Zhang,* Bihong Zhu, Pan Fu On the behalf of Alzheimer’s Disease Neuroimaging Initiative
Department of Neurology, Taizhou First People’s Hospital, Zhejiang, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Pan Fu
Department of Neurology, Taizhou First People’s Hospital, 218 Hengjie Road, Huangyan District, Taizhou City, Zhejiang Province, People’s Republic of China
Purpose: Although emerging evidence has suggested that clusterin is involved in the pathogenesis of Alzheimer’s disease (AD), the association of clusterin with synaptic degeneration in living human is unclear. In the present study, we aimed to examine the association of CSF clusterin levels with synaptic degeneration in individuals with different severities of cognitive impairment.
Patients and Methods: In the present study, we compared levels of clusterin in CSF among individuals with normal cognition (NC), mild cognitive impairment (MCI), and AD. Further, linear regression models were performed to examine the association of CSF clusterin with neurogranin (NG, reflecting synaptic degeneration) with adjustment of several potential confounders.
Results: We found that CSF clusterin levels were positively correlated with NG in the NC and MCI groups, but not the AD group. In all subjects, linear regression models suggested that clusterin levels were positively associated with NG levels independent of age, gender, apolipoprotein E4 (APOE4) genotype, clinical diagnosis, and CSF Aβ 42 levels.
Conclusion: Our data indicated that clusterin was associated with CSF NG levels among older individuals with different severities of cognitive impairment.
Keywords: clusterin, neurogranin, synaptic degeneration, Alzheimer’s disease, mild cognitive impairment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]